Sudarshan Chemical Industries Limited

Sources: Screener.in (C-MOTS) consolidated annual data; company Q4 FY26 deck; CRISIL (Sep 2026); Bajaj Broking (Aug 2026); ICICI Direct (FY22–FY23 gross profit). Derived ratios are computed by this report from those figures.

Comparability warning: FY25 includes Heubach for one month only (from 3 Mar 2025), and FY26 is the first full year. The FY24 net profit includes a ₹315 crore exceptional gain on the Pune land sale.

Income statement (₹ crore)

Footnotes:

• Gross profit: FY22/FY23 from ICICI Direct (Q4 FY23 note); FY26 from Bajaj Broking (₹48,154 mn, 49.2%).

• EPS conflict: Simply Wall St reports FY25 EPS of ₹7.86 and net income of ₹557.5 mn, versus Screener's ₹7.11 and ₹60 crore. The difference likely reflects attributable vs total profit or minority interest.

• Company-reported FY26 EPS before exceptional items is ₹6.6 (Q4 FY26 deck).

• Dividends: FY24 = ₹3.60 interim plus ₹1.00 final (Tickertape). FY26 = ₹5.00 final (250%), record date 11 Aug 2026.

• Screener payout ratios (27%, 23%, 63%) imply roughly ₹5.0, ₹1.5 and ₹4.5 respectively.

• Standalone FY26: revenue ₹2,396.7 crore and PAT ₹290.3 crore (+106%), boosted by subsidiary-related income (Scanx).

Margins and growth

Revenue CAGR:

• FY22–FY26 (4 years): 45.2%.

• FY21–FY26 (5 years, from ₹1,864 crore): 39.3%, consistent with Screener's 39%.

• Organic legacy growth FY21–FY24: about 10.9% CAGR.

Commentary — income statement:

FY22–FY23 margin compression: EBITDA margin fell from 16% (FY21) to 9.3% (FY23) as raw-material inflation, Chinese competition and energy costs outran pricing. ICICI Direct noted a sharp Q3 FY23 pigment-volume decline (-13.7%).

FY24 recovery: Legacy margins recovered to 12.5%. Net profit was inflated by the land gain.

FY25 (acquisition year): One month of a loss-making Heubach diluted margins. Acquisition costs (≈₹12 crore employee cost plus ≈₹8 crore one-offs, including an MIDC CETP settlement) and negative other income (FX/fair-value items) pushed the tax rate to 39%.

FY26 margin trough: Consolidated EBITDA margin was 6.2% because the acquired group ran at a 2.8% business EBITDA margin. Causes included:

• customer de-stocking after the insolvency;

• normalisation of surcharge-driven margins;

• release of inventorised overheads (−₹82 crore in Q4 FY26 alone);

• a Q3 FY26 Labour Code charge. This is ₹46 crore at One Sudarshan level per the Q3 deck; Scanx cites a ₹32 crore exceptional item, likely a different perimeter, so the two sources conflict.

Effective tax rate: 74% in FY26, because losses in European entities generate little tax shield.

Gross margin: Rose structurally to about 49% on the acquired group's richer specialty mix. It reached about 54% in Q1 FY27, which management guides should settle at a sustainable "50%+."

Inflection: Q4 FY26 revenue of ₹2,790 crore (+6.6% YoY, +36% QoQ) and Q1 FY27 business EBITDA of ₹247 crore (+63% YoY) mark the turn.

Balance sheet (₹ crore, 31 March)

Footnotes:

• Equity = equity capital plus reserves (Screener). FY26 total equity including NCI is ₹3,854 crore per Bajaj Broking. CRISIL's adjusted net worth is ₹2,506 crore after deducting the capital reserve on the bargain purchase.

• The FY26 cash, debt split and goodwill rows come from Bajaj Broking. Their long- plus short-term total (₹2,119 crore) differs from Screener total borrowings (₹2,473 crore), which include lease liabilities and other items. CRISIL also uses ₹2,473 crore including leases.

• CRISIL reports an unencumbered liquid surplus of ₹1,397–1,401 crore at 31 Mar 2026, including investments and deposits.

• Net debt was ₹922 crore at its peak, ₹934 crore in Dec 2025, ₹755 crore in Mar 2026 and ₹531 crore at 30 Jun 2026 (company). It is expected to fall towards zero after the VP4 proceeds (management, Sep 2026).

Commentary — balance sheet:

Transformation in FY25: Total assets quadrupled from ₹2,346 crore to ₹9,634 crore. The acquisition was funded mainly with equity (QIP ₹800 crore, preferential ₹195 crore, warrants) plus acquisition debt, and was a bargain purchase.

Gross vs net debt: Gross borrowings stayed roughly flat at about ₹2,400–2,500 crore through FY26. Net debt nevertheless fell sharply as inventory was liquidated: €29 million of acquired-group inventory reduction in Q4 FY26 against a €15–20 million target.

Working capital: Inventory days ballooned to 515 at FY25 year-end (an artefact of acquiring a full inventory with one month of sales) and normalised to 179 in FY26 (Screener). On the same date CRISIL reports 98 inventory days, 63 debtor days and 108 creditor days on its own methodology; the two sources conflict because of definitional differences.

Net working capital: improved to 23.6% of annualised sales by June 2026.

Cash flow (₹ crore)

Footnotes:

• FY24 net capex is negative because Screener's FCF nets the ₹356 crore land-sale proceeds. Gross capex was therefore about ₹89 crore.

• Bajaj Broking reports FY26 capex of ₹270 crore, net cash from operations of ₹344 crore, debt repayment of ₹316 crore and finance cost paid of ₹124 crore.

• No buyback authorisation exists.

Commentary — cash flow:

FY21–FY22 capex cycle: CWIP of about ₹280 crore reflected Roha/Mahad expansions and drove negative FCF.

FY23–FY24 harvest: Cash generation improved, and the land monetisation funded debt reduction (borrowings fell from ₹829 crore to ₹467 crore).

FY25: Investing outflow of ₹1,610 crore was the Heubach purchase, funded by ₹2,596 crore of financing inflow (equity plus acquisition loans).

FY26: CFO recovered to ₹344 crore. The ₹165 crore investing inflow most likely reflects liquidation of deposits or investments, which this report infers rather than confirms. ₹680 crore of financing outflow covered debt repayment, interest and dividends.

Forward view (CRISIL, FY27–FY29): Net cash accruals of ₹460–580 crore a year, against scheduled repayments of ₹120–345 crore and capex of ₹150–250 crore a year, leave room for prepayment.

Ratios

Footnotes:

• ROE uses average equity; FY21 equity was ₹744 crore.

• ROIC is not separately disclosed. The company's adjusted ROCE of 10.8% in FY26 rose to 22.7% annualised in Q1 FY27.

• Current ratio is not available in the sources reviewed.

• The FY24 ROE and ROA are inflated by the land gain; underlying FY24 ROE excluding the gain was about 4%.

Commentary — returns and leverage:

Return trend: Returns have been weak for three years (Screener 3-year average ROE about 3%). The causes are the FY23 cyclical trough, then the dilution from a large, loss-making acquisition plus a larger equity base after the QIP and preferential issue.

Medium-term targets (CRISIL): Adjusted gearing of 0.5–0.7x, net debt/EBITDA below 1.6x and interest coverage of 5–7x.

Q1 FY27 run-rate: Already ahead of those targets, with debt/equity of 0.2x and annualised ROCE of 22.7%. Some of the Q1 profit came from inventory-related gains, and seasonality flatters the annualisation.

Management guidance recap

FY27 acquired group: About €700 million of sales and €35 million of EBITDA. Q1 FY27 annualised (≈₹10,600 crore group revenue) already runs above this, but management declined to upgrade until after Q2.

Legacy: 12–13% revenue growth at 15–16% EBITDA margin.

FY28-29: Acquired-group EBITDA of €90–100 million. Group revenue of about ₹12,000 crore or more and EBITDA of ₹1,400–1,500 crore, with a net-cash balance sheet.

Consensus growth expectations (available broker estimates)

Revenue: +5–9% a year FY27E–FY28E (Bajaj: +5.3%, +8.7%).

EBITDA: +53% in FY27E and +29% in FY28E (Bajaj).

PAT: About ₹246–282 crore in FY27E, rising to ₹428–499 crore in FY28E (Bajaj, Arihant). This implies a 10x+ jump from FY26's ₹41 crore.

Bull case

1. Cost-led operating leverage on owned capacity. Business EBITDA rose 63% YoY in Q1 FY27 on only 5.4% revenue growth, and gross margin reached about 54%. If value capture delivers the ₹600–700 crore EBITDA bridge management describes as "in our control," FY28E EBITDA of about ₹1,160 crore is achievable without capex.

2. Balance-sheet de-risking is nearly complete. Net debt is down about 42% from the peak to ₹531 crore. VP4 proceeds of €76.5 million (≈₹713+ crore) should leave the group net-cash, which turns free cash flow toward dividends and growth and reduces equity risk.

3. Valuation re-rating. At about 11x FY27E and 8x FY28E EV/EBITDA, with the #2 global pigment platform bought out of insolvency at about 0.13x historical sales, delivery of the €90–100 million target would justify a re-rating toward global specialty-chemicals multiples.

Bear case

1. Turnaround fragility. Acquired-group margin was only 6.5% in Q1 FY27 and helped by inventory-related gains. Gross margin of 54% is above the guided 50%+, so normalisation and pass-through give-back if oil falls could cap progress. FY26 shows how fast the group can swing to losses (Q3 FY26: −₹116 crore).

2. Structural and cyclical demand headwinds. US/EU coatings and automotive demand is subdued, plastics buying is hand-to-mouth, and printing-ink volumes are in structural decline. Legacy pigment sales grew just 0.4% in FY26, and Q1 FY27 legacy growth was partly intercompany.

3. Execution, governance and regulatory noise. An unquantified European restructuring charge, the One SAP go-live risk, senior legal/CS turnover, an open Maharashtra GST search at the parent, multiple non-GAAP EBITDA definitions and delayed past reporting all raise the risk premium. The trailing P/E of about 96–136x leaves no room for slippage.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict

Sudarshan Chemical Industries has made the boldest strategic move in Indian specialty chemicals this decade. It bought the insolvent Heubach Group, itself the owner of Clariant's former pigments franchise, for €127.5 million, and became the world's second-largest pigment producer almost overnight. The first full year (FY26) was as painful as the turnaround thesis allowed. Consolidated revenue nearly tripled to ₹9,787 crore, but net profit fell to ₹41 crore, the acquired business earned a 2.8% EBITDA margin, and Q3 FY26 brought a ₹116 crore loss.

The evidence since Q4 FY26 suggests the inflection is real rather than seasonal:

• Acquired-group EBITDA beat its Q4 projection.

• Q1 FY27 business EBITDA rose 63% on flat-ish volumes.

• Gross margins reached record levels.

• Net debt fell to ₹531 crore.

• The legacy Indian business reaccelerated to 22% growth at a 15.3% margin.

The VP4 divestiture at about 18.7x EBITDA shows management will monetise non-core assets at good prices and use the proceeds to deleverage.

The central analytical judgement is that the remaining upside is mostly within management's control. It depends on cost and footprint value capture, inventory release and GKA recapture on capacity already owned, rather than on a demand recovery. That makes the risk executional: SAP consolidation, European labour restructuring and pricing discipline as input costs swing.

At roughly 11x FY27E and 8x FY28E EV/EBITDA, the market is pricing partial, not full, delivery of the €90–100 million EBITDA ambition. The bar for a re-rating is a credible step-up beyond the €35 million FY27 guide, with no large restructuring surprise and a clean resolution of the October 2026 GST search.

Balanced view: constructive, with high execution risk. Sudarshan is a levered, idiosyncratic turnaround on a structurally advantaged global platform. Investors should watch quarterly acquired-group margins and net debt closely and treat any slippage in the cost programme as the key thesis breaker.